As an early-stage proteomic diagnostics company, we’re on a mission to expand newborn screening programs through the early identification of treatable genetic conditions that, if left undetected at birth, can advance to irreversible or fatal outcomes later in childhood or early adulthood. To help create awareness of and expand access to these life-saving screening tests, Key Proteo welcomes the opportunity to listen, learn, and collaborate with patient advocacy groups whose voices must be heard.

With NBS partner programs already in place at Washington State Department of Health and Alberta’s Public Health Lab (ProvLab, Canada), we understand the intricacies of public health-based newborn screening programs and we can develop flexible, adaptable programs that align with most public health laboratories’ operations and budgets.

As Key Proteo looks to expand its footprint outside the U.S., we welcome the opportunity to collaborate with other laboratories, instrument manufacturers, and distributors that currently offer or are interested in offering Newborn Screening programs in their respective countries or regions.

For pharmaceutical companies, Key Proteo offers an opportunity to accelerate clinical development programs by helping to identify patients with rare genetic conditions, thus helping with the selection or exclusion of patients to be enrolled in clinical trials for pipeline therapeutics.

As hospitals and health systems recognize the power of early detection and increasingly look to expand newborn screening programs to include additional treatable genetic conditions, Key Proteo has extensive expertise rooted in its development and ongoing collaborative efforts with Seattle Children’s Hospital and the University of Washington. Our experience allows us to build high-quality, value-creating partnerships that help improve patient outcomes, increase revenue, minimize costs, and align with clinical laboratory services and operations.